Language selection

Search

Archived — Teva / Ratiopharm divests products pursuant to the terms of consent agreement

OTTAWA, November 30, 2010 — The Competition Bureau is pleased to announce that Teva Pharmaceutical Industries Ltd. has completed the divestiture of assets and associated licences relating to the sale and supply of certain generic drugs to Sandoz Canada Inc., in accordance with the terms of a July 2010 Consent Agreement with the Bureau.

The Bureau concluded that the merger of Teva and the Merckle Group (carrying on business as ratiopharm) would likely lead to a substantial lessening of competition in the sale and supply of acetaminophen oxycodone tablets and morphine-sulfate sustained-release tablets in Canada, which are used for moderate-to-severe pain relief.


For media enquiries, please contact:
Media Relations
Telephone: 819‑994‑5945
Email: ic.media‑cb‑bc.ic@canada.ca

For general enquiries, please contact:
Information Centre
Competition Bureau
Telephone: 819‑997‑4282
Toll free: 1‑800‑348‑5358
TTY (hearing impaired): 1‑866‑694‑8389
www.competitionbureau.gc.ca
Enquiries/Complaints
Stay connected

Date modified: